Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xenical OTC Switch Plans Underway; GSK Pays $100 Mil. For Rights

Executive Summary

Roche and GlaxoSmithKline appear to be moving quickly on an Rx-to-OTC switch application for the anti-obesity agent Xenical (orlistat)

You may also be interested in...



Sanofi-Aventis To Begin Long-Term Acomplia Cardio Safety Study By Fall

Sanofi-Aventis will begin conducting a four-to-five year Acomplia (rimonabant) cardiovascular safety study by the fall, the company said

Sanofi-Aventis To Begin Long-Term Acomplia Cardio Safety Study By Fall

Sanofi-Aventis will begin conducting a four-to-five year Acomplia (rimonabant) cardiovascular safety study by the fall, the company said

Obesity Drugs May Be Covered Under Part D; CMS Invites Limits On Viagra

Drugs to treat "morbid obesity" may be covered by Medicare Part D plans despite the exclusion of "weight loss agents" from the program, CMS indicated in the final rules implementing the Medicare Rx benefit

Related Content

Topics

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel